国药一致(000028.SZ)：预计2025年度净利润同比增长64.20%到89.11%

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (国药一致), expects a significant increase in net profit for the fiscal year 2025, indicating strong resilience and operational vitality despite a challenging market environment [1] Financial Performance - The company anticipates a net profit attributable to shareholders ranging from 1,055 million to 1,215 million yuan for 2025, representing a year-on-year growth of 64.20% to 89.11% [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 996 million and 1,156 million yuan, with a year-on-year increase of 71.38% to 98.91% [1] Operational Strategy - In a complex and competitive industry landscape, the company demonstrates strong development resilience through proactive structural adjustments and cost management, effectively curbing profit decline and achieving overall performance recovery [1] - The distribution business remains a cornerstone of the company's operations, continuing to show stable growth [1] - The company enhances operational quality by strengthening its procurement system, optimizing product structure, and strategically adjusting store layouts [1]